BRPI0515371A - hidantoìnas substituìdas - Google Patents

hidantoìnas substituìdas

Info

Publication number
BRPI0515371A
BRPI0515371A BRPI0515371-9A BRPI0515371A BRPI0515371A BR PI0515371 A BRPI0515371 A BR PI0515371A BR PI0515371 A BRPI0515371 A BR PI0515371A BR PI0515371 A BRPI0515371 A BR PI0515371A
Authority
BR
Brazil
Prior art keywords
compounds
useful
substituted hydantoins
diseases
hidantoin
Prior art date
Application number
BRPI0515371-9A
Other languages
English (en)
Inventor
Robert Alan Goodnow
Nicholas John Silvester Huby
Norman Kong
Lee Apostle Mcdermott
John Anthony Moliterni
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0515371A publication Critical patent/BRPI0515371A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

HIDANTOìNAS SUBSTITUìDAS. A presente invenção refere-se a compostos da fórmula que são úteis no tratamento de doenças caracterizadas pela hiperatividade de MEK. Por conseguinte os compostos são úteis no tratamento de doenças tais como câncer, distúrbios cognitivos e do SNC e doenças inflamatórias/autoimunes.
BRPI0515371-9A 2004-09-17 2005-09-15 hidantoìnas substituìdas BRPI0515371A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61065504P 2004-09-17 2004-09-17
PCT/EP2005/009926 WO2006029862A1 (en) 2004-09-17 2005-09-15 Substituted hydantoins for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0515371A true BRPI0515371A (pt) 2008-07-22

Family

ID=35447646

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515371-9A BRPI0515371A (pt) 2004-09-17 2005-09-15 hidantoìnas substituìdas

Country Status (16)

Country Link
US (1) US7371869B2 (pt)
EP (1) EP1791837B1 (pt)
JP (1) JP4685873B2 (pt)
KR (1) KR100869681B1 (pt)
CN (1) CN101023079B (pt)
AR (1) AR051290A1 (pt)
AT (1) ATE440097T1 (pt)
AU (1) AU2005284293B2 (pt)
BR (1) BRPI0515371A (pt)
CA (1) CA2579130A1 (pt)
DE (1) DE602005016127D1 (pt)
ES (1) ES2329264T3 (pt)
MX (1) MX2007003166A (pt)
RU (1) RU2393156C2 (pt)
TW (1) TW200621766A (pt)
WO (1) WO2006029862A1 (pt)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
CN101778839A (zh) 2007-08-16 2010-07-14 霍夫曼-拉罗奇有限公司 取代的乙内酰脲
WO2009080523A1 (en) 2007-12-20 2009-07-02 F. Hoffmann-La Roche Ag Substituted hydantoins as mek kinase inhibitors
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
AU2010313622B2 (en) 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
CA2816188A1 (en) 2010-10-29 2012-05-03 Marion Hitchcock Substituted phenoxypyridines
KR101472175B1 (ko) * 2012-02-17 2014-12-15 중앙대학교 산학협력단 신규한 2-아미노티아졸 유도체 및 이를 유효성분으로 포함하는 항암용 조성물
EP3191481B1 (en) * 2014-09-12 2020-11-25 Ariagen, Inc. Efficient and scalable systhesis of 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester and its structural analogs
RU2605091C2 (ru) * 2015-05-12 2016-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития" 2-амино-1-арил-5-(3,3-диметил-2-оксобутилиден)-4-оксо-n-(тиазол-5-ил)-4,5-дигидро-1н-пиррол-3-карбоксамиды, проявляющие противоопухолевую и антирадикальную активность, способ их получения и фармацевтическая композиция на их основе
CN113480530A (zh) 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
MX391501B (es) 2017-04-18 2025-03-21 Fochon Pharmaceuticals Ltd Agentes inductores de apoptosis
KR20200089718A (ko) 2017-11-20 2020-07-27 아리아젠, 인크. 인돌 화합물 및 이의 용도
US10555558B2 (en) 2017-12-29 2020-02-11 Rai Strategic Holdings, Inc. Aerosol delivery device providing flavor control
CA3137027A1 (en) 2019-04-15 2020-10-22 Ariagen, Inc. Chiral indole compounds and their use
CN112341446B (zh) * 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757046B2 (en) 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
KR19990012061A (ko) 1997-07-26 1999-02-25 성재갑 파네실 전이효소 저해제로 유용한 하이덴토인 유도체
AU5227001A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
WO2003008365A2 (en) * 2001-07-19 2003-01-30 Pharmacia Italia S.P.A. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
BRPI0514515A (pt) * 2004-08-17 2008-06-10 Hoffmann La Roche hidantoìnas substituìdas

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP3028699A1 (en) 2010-02-25 2016-06-08 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
ATE440097T1 (de) 2009-09-15
ES2329264T3 (es) 2009-11-24
AU2005284293A1 (en) 2006-03-23
US7371869B2 (en) 2008-05-13
JP2008513397A (ja) 2008-05-01
US20060063814A1 (en) 2006-03-23
KR20070043895A (ko) 2007-04-25
TW200621766A (en) 2006-07-01
WO2006029862A1 (en) 2006-03-23
KR100869681B1 (ko) 2008-11-21
CN101023079A (zh) 2007-08-22
DE602005016127D1 (de) 2009-10-01
AR051290A1 (es) 2007-01-03
CN101023079B (zh) 2010-05-05
CA2579130A1 (en) 2006-03-23
EP1791837B1 (en) 2009-08-19
RU2007114125A (ru) 2008-10-27
AU2005284293B2 (en) 2011-10-06
EP1791837A1 (en) 2007-06-06
JP4685873B2 (ja) 2011-05-18
RU2393156C2 (ru) 2010-06-27
MX2007003166A (es) 2007-05-15

Similar Documents

Publication Publication Date Title
BRPI0514515A (pt) hidantoìnas substituìdas
CR10208A (es) Inhibidores de quinasa basados en la hidantoina
TW200621766A (en) Substituted hydantoins
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
BRPI0512856A (pt) métodos e reagentes para o tratamento de distúrbios metabólicos
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
BRPI0514017A (pt) indazóis úteis no tratamento de doenças cardiovasculares
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
EA201100299A1 (ru) Органические соединения
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
TW200509892A (en) Novel aminobenzophenone compounds
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2011008899A (es) Nuevas orto-aminoamidas para el tratamiento del cancer.
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA200700909A1 (ru) Азаиндолкарбоксамиды
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer
BRPI0713381A2 (pt) composto, composição farmacêutica, e, método para o tratamento de uma doença

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2271 DE 15/07/2014.